[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

Roche reported third-quarter sales growth of 7% at constant exchange rates (CER) and 8% in CHF, citing strong momentum. In the first nine months of 2026, Group sales rose 6% at CER, 1% in CHF and 7% in USD, driven by demand for innovative medicines and diagnostics.

Analysis

The investable signal is that underlying demand appears stronger than reported-CHF results suggest; the gap makes currency translation a material near-term noise factor, not evidence by itself of deteriorating operating momentum. That supports a cautiously constructive read on Roche, but sales growth alone cannot establish earnings quality: product mix, launch contribution, pricing, and cost growth will determine whether revenue converts into margin and EPS upside.

The 1–3 month catalyst is the full earnings detail and any change to guidance, especially whether growth is broad across medicines and diagnostics or concentrated in a few products. A broad-based result would strengthen the durability case; concentration or weaker profitability would make the headline growth less valuable. Over 6–18 months, sustained innovation-led demand could support share gains, but this announcement provides no product-level evidence to quantify competitive displacement. Read-through to Novartis or other healthcare peers is therefore limited.

The contrarian risk is treating a positive CER figure as a clean earnings beat without comparing it with expectations or checking FX assumptions. With no valuation, consensus, or margin data supplied, this supports monitoring rather than chasing a standalone event-driven move.

Key Decisions for Investors

• Keep Roche on a constructive watchlist; do not add solely on the sales headline. Verify the reported result against consensus and inspect product-level growth, segment mix, and operating-margin commentary.
• At the next detailed results, favor a long only if management maintains or raises guidance and growth is broad-based without margin deterioration. Falsification: guidance is cut, growth is concentrated, or operating profitability weakens despite CER sales growth.
• Track CHF translation separately from underlying demand when assessing reported results. Avoid extrapolating the nine-month currency drag into future periods without updated FX assumptions.
• Do not use this release alone as a pair-trade signal against Novartis or other pharma peers; the available data do not establish relative valuation, growth, or product-level competitive effects.